Background and Objective:Materials and Methods: Results: Conclusion: Samples were collected before Methotrexate treatment. The transcriptomes were determined.

Slides:



Advertisements
Similar presentations
Original Figures for "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring"
Advertisements

Exercise 1 In the ISwR data set alkfos, do a PCA of the placebo and Tamoxifen groups separately, then together. Plot the first two principal components.
Predictive Analysis of Gene Expression Data from Human SAGE Libraries Alexessander Alves* Nikolay Zagoruiko + Oleg Okun § Olga Kutnenko + Irina Borisova.
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
DISSECTING DISEASE-SPECIFIC DIFFERENCES IN RA AND OA BY TRANSCRIPTOME ANALYSES OF SYNOVIAL TISSUE, BLOOD AND BONE MARROW MONOCYTES Biljana Smiljanovic.
Targeted (Enrichment) Design. Prospective Co-Development of Drugs and Companion Diagnostics 1. Develop a completely specified genomic classifier of the.
Minimum Redundancy and Maximum Relevance Feature Selection
Supervised classification performance (prediction) assessment Dr. Huiru Zheng Dr. Franscisco Azuaje School of Computing and Mathematics Faculty of Engineering.
Genomic signatures to guide the use of chemotherapeutics Authors: Anil Potti et. al Presenter: Jong Cheol Jeong.
1 Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data Presented by: Tun-Hsiang Yang.
Gene expression profiling identifies molecular subtypes of gliomas
Automated analysis of cytometric profiles of synovial fluid and peripheral blood in rheumatoid arthritis Till Sörensen 1, Ursula Schulte-Wrede 2, Silvia.
2015 AprilUNIVERSITY OF HAIFA, DEPARTMENT OF STATISTICS, SEMINAR FOR M.A 1 Hastie, Tibshirani and Friedman.The Elements of Statistical Learning (2nd edition,
Biomarker and Classifier Selection in Diverse Genetic Datasets J AMES L INDSAY 1 E D H EMPHILL 2 C HIH L EE 1 I ON M ANDOIU 1 C RAIG N ELSON 2 U NIVERSITY.
Prediction model building and feature selection with SVM in breast cancer diagnosis Cheng-Lung Huang, Hung-Chang Liao, Mu- Chen Chen Expert Systems with.
Molecular Diagnosis Florian Markowetz & Rainer Spang Courses in Practical DNA Microarray Analysis.
Study Designs Afshin Ostovar Bushehr University of Medical Sciences Bushehr, /4/20151.
Acknowledgement: BTCure IMI grant agreement no ArthroMark grant no 01EC1009A Identification of co-expression networks of inflammatory response.
Cell-specific type I Interferon signatures in autoimmunity and viral infection: what makes the difference? Chieko Kyogoku 1, Biljana Smiljanovic 1, Joachim.
Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.
NT CVD : Development and Validation of new Diagnostic, Preventive and Therapeutic Tools for the Prevention of Cardiovascular Disease in Chronic Kidney.
SYNOVIAL TISSUE TRANSCRIPTOME AND SYNOVIAL FLUID PROTEOME HAVE STRONGER DISCRIMINATORY POWER THAN SERUM IN DISSECTING INFLAMMATION IN RHEUMATOID ARTHRITIS.
MicroRNA implication in urinary bladder cancer A. Zaravinos 1, J. Radojicic 3, G.I. Lambrou 2, D. Volanis 1,4, D. Delakas 4, E.N. Stathopoulos 3, D.A.
Transcriptomic Analysis of Peripheral Blood Mononuclear Cells in Rapid Progressors in Early HIV Infection Identifies a Signature Closely Correlated with.
Marc Bonin Department of Rheumatology and Clinical Immunology Charité University Hospital Charitéplatz 1 D Berlin Germany Tel: +49(0)
1 Critical Review of Published Microarray Studies for Cancer Outcome and Guidelines on Statistical Analysis and Reporting Authors: A. Dupuy and R.M. Simon.
EPA’s Bioassessment Performance and Comparability “Guidance”
Jun-Won Suh Intelligent Electronic Systems Human and Systems Engineering Department of Electrical and Computer Engineering Speaker Verification System.
Apostolos Zaravinos and Constantinos C Deltas Molecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, Department of Biological.
A Short Overview of Microarrays Tex Thompson Spring 2005.
Acknowledgements Contact Information Anthony Wong, MTech 1, Senthil K. Nachimuthu, MD 1, Peter J. Haug, MD 1,2 Patterns and Rules  Vital signs medoids.
Comparative analysis between Rheumatoid arthritis and arthritis model – study of the functional components in expression profiles of synovitis Irene Ziska.
The Use of Predictive Biomarkers in Clinical Trial Design Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute
Evolutionary Algorithms for Finding Optimal Gene Sets in Micro array Prediction. J. M. Deutsch Presented by: Shruti Sharma.
Identification of gene co-expression networks associated with different cellular and immunological states Marc Bonin 1, Jekaterina Kokatjuhha 1, Stephan.
Introduction to Microarrays Kellie J. Archer, Ph.D. Assistant Professor Department of Biostatistics
Computational Approaches for Biomarker Discovery SubbaLakshmiswetha Patchamatla.
A comparative study of survival models for breast cancer prognostication based on microarray data: a single gene beat them all? B. Haibe-Kains, C. Desmedt,
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
Molecular Classification of Cancer Class Discovery and Class Prediction by Gene Expression Monitoring.
A clinical database for networking in multicenter studies Ulrike Haase 1, Marc Bonin 1, Stephan Flemming 2, Frank Buttgereit 1, Till Sörensen 1, Thomas.
EBM --- Journal Reading Presenter :呂宥達 Date : 2005/10/27.
Identification of co-expression networks by comparison of a multitude of different functional states of genome activity Marc Bonin 1, Stephan Flemming.
Pan-cancer analysis of prognostic genes Jordan Anaya Omnes Res, In this study I have used publicly available clinical and.
BIOCONPAGES Comparison of DNA-methylation and gene expression in different immune cells Marc Bonin 1, Lorette Weidel 1, Pascal Schendel 1, Sascha Johannes.
 Gene-expression profiles from synovial tissue biopsies and blood monocytes were generated from patients with RA and OA.  Transcriptome analysis of synovial.
Nawanol Theera-Ampornpunt, Seong Gon Kim, Asish Ghoshal, Saurabh Bagchi, Ananth Grama, and Somali Chaterji Fast Training on Large Genomics Data using Distributed.
Introduction Background Medical decision support systems based on patient data and expert knowledge A need to analyze the collected data in order to draw.
Date of download: 6/20/2016 Copyright © The American College of Cardiology. All rights reserved. From: Precision Medicine in Patients With Resistant Hypertension.
Raphael Sandaltzopoulos, PhD, MBA Professor at MBG (Molecular Biology) Lab. of Gene Expression, Molecular Diagnosis and Modern Therapeutics,
Classifiers!!! BCH364C/391L Systems Biology / Bioinformatics – Spring 2015 Edward Marcotte, Univ of Texas at Austin.
Combined analysis of DNA-methylation and transcription profiles in different immune cells identifies hot spots of gene regulation by DNA methylation Marc.
R3 조 욱 Salivary Transcriptomic Biomarkers for Detection of Resectable Pancreatic Cancer Articles LEI ZHANG, JAMES J. FARRELL, HUI ZHOU, DAVID ELASHOFF,
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
miRNA-targets cross-talks: key players in glioblastoma multiforme
National Healthcare Science Week 2017
Classification with Gene Expression Data
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,
Classifiers!!! BCH339N Systems Biology / Bioinformatics – Spring 2016
Introduction to translational and clinical bioinformatics Connecting complex molecular information to clinically relevant decisions using molecular.
Integrated microRNA-mRNA profiling identifies molecular biomarkers in bladder outlet obstruction-induced lower urinary tract dysfunction Fiona C. Burkhard1,
A bioinformatic analysis of microRNAs role in osteoarthritis
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,
Figure 3 Transcriptome studies performed in the target
Class Prediction Based on Gene Expression Data Issues in the Design and Analysis of Microarray Experiments Michael D. Radmacher, Ph.D. Biometric Research.
Volume 149, Issue 2, Pages (February 2016)
Plasma Biomarkers in Graft-versus-Host Disease: A New Era?
Advisor: Dr.vahidipour Zahra salimian Shaghayegh jalali Dec 2017
Outlines Introduction & Objectives Methodology & Workflow
Chaoran Hu1,4, Xiao Tan2,4, Qing Pan3, Yong Ma4, Jaejoon Song4
Presentation transcript:

Background and Objective:Materials and Methods: Results: Conclusion: Samples were collected before Methotrexate treatment. The transcriptomes were determined by Affymetrix technology and the therapeutic response level by clinical follow-up in an observational study. To select potential molecular predictors and to compare the molecular classifiers between different clinical response groups, various R-packages were applied. Good to very good predictors could be identified by using the Limma and the Lasso algorithms in the mRNA transcriptoms, which enabled to classify nearly without an error by linear discrimination analysis (LDA). Between groups of genes determined by different selection methods an overlap up to 40% could be reached and hierachical clustering generated nearly perfect grouping. Nevertheless among mRNAs the heatmap patterns seemed to be in part heterogeneous. The analysis was repeated after splitting the samples into two groups with respect to the expression level of the gene HLA-DRB4 (Fig.3), a gene locus, which is genetically important for risk prediction in rheumatoid arthritis. Between the molecular predictors of response for the two groups of HLA-DRB4 positive and negative patients no overlap could be found. Also the overlap with the predictors of the combined group decreased notable. Similar results were observed when analysing the microRNA transcriptoms. Finally the samples were seperated into a test and a training set for an independent validation. Only the investigation of the groups spitted by HLA criteria showed adequate reproducibility whereas the combined group obviously generated unstable predictors. In summary, combining the advantages of different algorithms like Limma, Lasso and LDA for selecting and testing molecular predictors for clinical response increases the dignostic power of biomarkers. Nevertheless, appropriate characterization and splitting into distinct subgroups is essential to increase reproducibility and validity in biomarker development. Treatment of chronic arthritis is challenged by the need to adapt dosis or exchange therapeutic agents without prior knowlegde of the individual response characteristics. With genomewide screening of transcriptional activities in whole blood, we hope to identify molcular patterns that help to distinguish responders from non-responders prior to treatment and thus may support therapeutic decisions. Acknowledgement: BTCure IMI grant agreement no Figure 3 ArthroMark grant no 01EC1009A Prediction for successful treatment of methotrexate in rheumatoid arthritis with mRNA and miRNA microarraydata Pascal Schendel, Marc Bonin, Karsten Mans, Florian Heyl, Jekaterina Kokatjuhha, Sascha Johannes, Irene Ziska, Biljana Smiljanovic, Till Sörensen, Bruno Stuhlmüller, Thomas Häupl Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany Figure 1 Marc Bonin Department of Rheumatology and Clinical Immunology Charité University Hospital Charitéplatz 1 D Berlin Germany Tel: +49(0) Fax: +49(0) Web: Contacts: number of transcripts transcript selection classification HLA-DRB4 Groups (mRNA): HLA-DRB4 negative: min. intensity: 4, max. intensity: 66 HLA-DRB4 positive: min. intensity: 1464, max. intensity: 5354 HLA-DRB4- positive Group with 19 miRNAs, after Kruskal-Wallis-Test. Figure 2 miRNA biomarker without grouping by HLA-DRB4 positive and negative. Figure 4 HLA-DRB4- negative Group with 17 miRNAs, after Kruskal-Wallis-Test. Figure 5 HLA-DRB4- positive Group with 5 miRNAs, after Kruskal-Wallis-Test & SVM. HLA-DRB4- negative Group with 4 miRNAs, after Kruskal-Wallis-Test. HLA-DRB4- positive Group with 3 miRNAs, after Lasso. (100 % overlap with Kruskal- Wallis-Test & SVM) HLA-DRB4- negative Group with 4 miRNAs, after Lasso. (75 % overlap with Kruskal-Wallis-Test & SVM) ROC of cross validation: HLA-DRB4- positive Group with 5 miRNAs, after Kruskal-Wallis-Test & SVM. ROC of cross validation: HLA-DRB4- negative Group with 4 miRNAs, after Kruskal-Wallis-Test. Reciever Operation Characteristic